Actelion is a Swiss biopharmaceutical company founded in 1997. Located in South San Francisco, our US offices are situated in the hub of California's pharmaceutical and biotech development region. Today with about 2,500 people in 30 countries we focus on discovery, development and marketing of innovative drugs for highly unmet medical needs Actelion combines the innovation, entrepreneurial spirit and flexibility of biotech with the financial, risk management, regulatory and commercial discipline of a large pharmaceutical company. We have ambitious plans to keep improving and growing – and are looking for people as innovative as ourselves.
In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Actelion's medicines have helped to expand and strengthen Janssen's portfolio with leading, differentiated in-market medicines and promising late-stage compounds. Janssen has added Pulmonary Hypertension as a therapeutic area of focus to maintain the leadership position Actelion has built in this important disease area. Learn more at www.actelion.com. Follow us on Twitter @actelion_com.